scFv Antibody: Principles and Clinical Application

Table 1

FDA-approved therapeutic antibodies [3].

Brand name	Antibody	Target	Source	Year	Indication
Orthoclone^®	Muromonab-CD3	CD3	All rodent	1986	Transplantation rejection
ReoPro^TM	Abciximab	GPIIb, IIIa	Chimeric	1994	High-risk angioplasty
Rituxan^TM	Rituximab	CD20	Chimeric	1994	Non-Hodgkin’s lymphoma, rheumatoid arthritis
Zenapax^®	Daclizumab	CD25	Humanized	1997	Transplantation rejection
REMICADE^®	Infliximab	TNF-a	Chimeric	1998	Crohn’s disease
Simulect^®	Basiliximab	CD25	Chimeric	1998	Transplantation rejection
Synagis^TM	Palivizumab	RSV F protein	Humanized	1998	RSV infection
Herceptin^®	Trastuzumab	HER-2	Humanized	1998	Breast cancer
Mylotarg^TM	Gemtuzumab	CD33	Humanized	2000	Acute Myeloid Leukemia
Campath^®	Alemtuzumab	CD52	Humanized	2001	Chronic lymphotic leucemia, T-cell lymphoma
Zevalin^®	Ibritumomab tiuxetan	CD20	Murine—with yttrium-90 or indium-111	2002	Non-Hodgkin’s lymphoma
HUMIRA^TM	Adalimumab	TNF-a	Human	2002	Inflammatory diseases: mostly autoimmune disorders like rheumatoid arthritis, psoriadic arthritis, Morbus Chron
Bexxar^®	Tositumomab	CD20	Murine: covalentely bound to Iodine 131	2003	Non-Hodgkin’s lymphoma
Xolair^®	Omalizumab	IgE	Humanized	2003	Severe (allergic) asthma
Avastin^TM	Bevacizumab	VEGF	Humanized	2004	Metastatic colorectal cancer, nonsmall cell lung cancer, metastatic breast cancer
TYSABRI^®	Natalizumab	α4 subunit of a4β1	Humanized	2004	Multiple Sclerosis, Chron’s disease
Erbitux^TM	Cetuximab	EGFR	Chimeric	2004	Colorectal cancer, head and neck cancer
Vectibix^TM	Panitumumab	EGFR	Human	2006	Metastatic colorectal carcinoma
LUCENTIS^TM	Ranibizumab	VEGF-A	Humanized Fab	2006	Wet macular degeneration
Soliris^®	Eculizumab	CD59	Humanized	2007	Paroxysmal nocturnal hemoglobinuria
CIMZIA^®	Certolizumab pegol	TNF-a	Humanized (Fab)	2008	Crohn’s disease, rheumatoid arthritis
Simponi^TM	Golimumab	TNF-a	Human	2009	Rheumatoid and psoriatic arthritis, active ankylosing spondylitis